Isoform-selective inhibitory profile of 2-imidazoline-substituted benzene sulfonamides against a panel of human carbonic anhydrases

Claudiu T. Supuran, Stanislav Kalinin, Muhammet Tanç, Pakornwit Sarnpitak, Prashant Mujumdar, Sally Ann Poulsen, Mikhail Krasavin

Research output: Contribution to journalArticleResearchpeer-review

21 Citations (Scopus)


A series of novel benzene sulfonamides (previously evaluated as selective cyclooxygenase-2 inhibitors) has been profiled against human carbonic anhydrases I, II, IV and VII in an attempt to observe the manifestation of the well established “tail” approach for designing potent, isoform-selective inhibitors of carbonic anhydrases (CAs, EC The compounds displayed an excellent (pKi 7–8) inhibitory profile against CA II (a cytosolic anti-glaucoma and anti-edema biological target) and CA VII (also a cytosolic target believed to be involved in epilepsy and neuropathic pain) and a marked (1–2 orders of magnitude) selectivity against cytosolic isoform CA I and membrane-bound isoform CA IV. The separation of the CA II and CA IV (both of which are catalytically active isoforms, highly sensitive to sulfonamide-type inhibitors) is particularly remarkable and is adding significantly to the global body of data on the chemical biology of carbonic anhydrases.

Original languageEnglish
Pages (from-to)197-202
Number of pages6
JournalJournal of Enzyme Inhibition and Medicinal Chemistry
Publication statusPublished - 1 Nov 2016
Externally publishedYes


  • 2-imidazolines
  • Carbonic anhydrases
  • cyclooxygenase-2 inhibitors
  • dual active site architecture
  • isoform selectivity
  • lipophilic appendages
  • tail approach

Cite this